The phase 2 PORT study is an open-label, randomized, cross-over study which compared pharmacokinetics, safety and tolerability of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma who had received at least two lines of prior therapy and were refractory to a proteasome inhibitor and an immunomodulatory drug.

The study was fully recruited in April 2021, and top line results were presented in Q3 2021. The study was terminated in January 2022 during long-term follow-up.